0K16 Stock Overview A performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Evolus Historical stock prices Current Share Price US$11.03 52 Week High US$17.81 52 Week Low US$10.00 Beta 1.29 1 Month Change -18.61% 3 Month Change -33.22% 1 Year Change 6.23% 3 Year Change 63.81% 5 Year Change -22.62% Change since IPO -44.43%
Recent News & Updates
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.30 loss in 3Q 2023) Nov 07
Evolus, Inc. Provides Earnings Guidance for the Year 2024 Nov 07
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation Nov 01
Evolus, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
New minor risk - Share price stability Aug 02
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.32 loss in 2Q 2023) Aug 01 See more updates
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.30 loss in 3Q 2023) Nov 07
Evolus, Inc. Provides Earnings Guidance for the Year 2024 Nov 07
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation Nov 01
Evolus, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
New minor risk - Share price stability Aug 02
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.32 loss in 2Q 2023) Aug 01
Evolus, Inc. Raises Financial Guidance for the Full Year of 2024 Aug 01
Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee Jul 01
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products Jun 24
Chairman of the Board recently sold US$97k worth of stock Jun 09
Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting May 23
President recently sold US$204k worth of stock May 16
Forecast breakeven date moved forward to 2025 May 09
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024 May 09
First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 1Q 2023) May 08
Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau Apr 18
Evolus, Inc. Announces Board Changes Apr 04
President recently sold US$1.3m worth of stock Mar 22 Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million. Mar 11
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024 Mar 08
Full year 2023 earnings released: US$1.08 loss per share (vs US$1.33 loss in FY 2022) Mar 08
Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Feb 23
Evolus, Inc. Announces Earnings Guidance for 2024 Jan 17
Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications Jan 05
New minor risk - Shareholder dilution Dec 22
President recently sold US$822k worth of stock Dec 11
New minor risk - Insider selling Nov 15
New major risk - Financial position Nov 12
No longer forecast to breakeven Nov 08
Evolus, Inc. Raises Earnings Guidance for the Full Year 2023 Nov 08
Insufficient new directors Nov 08
Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau Nov 07
Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26
Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer Aug 22
President recently sold US$152k worth of stock Aug 18
Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers Aug 09
New major risk - Negative shareholders equity Aug 04
Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.42 loss in 2Q 2022) Aug 03
Evolus, Inc. Revises Revenue Guidance for the Year 2023 Jul 29
Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy Jun 30
Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R) Jun 23
First quarter 2023 earnings released: US$0.26 loss per share (vs US$0.31 loss in 1Q 2022) May 10
Evolus, Inc. Provides Revenue Guidance for the Year 2023 May 10
Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023 May 06
Insufficient new directors Mar 31
Full year 2022 earnings released: US$1.33 loss per share (vs US$0.94 loss in FY 2021) Mar 09
Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance Jan 29
Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia Jan 24
Evolus, Inc. Provides Earnings Guidance for the Year 2023 Jan 19
Insufficient new directors Jan 18
Forecast to breakeven in 2025 Jan 04
Insufficient new directors Jan 04
Insufficient new directors Nov 25
Evolus, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 09
Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Insufficient new directors Oct 07
Independent Director recently bought US$91k worth of stock Sep 07
Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022 Aug 31
Forecast to breakeven in 2024 Aug 04
Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.30 loss in 2Q 2021) Aug 03
Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022 Aug 03
Insufficient new directors Aug 02
Evolus, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 20
Evolus, Inc. Completes Patient Enrollment in Phase II Clinical Study Evaluating Extra-Strength Dose of Jeuveau Jul 13
Evolus, Inc. Announces Dermatologic Surgery Published A New Post Hoc Analysis of Its Phase III Studies Comparing Millennial Patients to Non-Millennials Jun 04
Independent Director recently sold US$138k worth of stock May 19 Evolus, Inc. Revises Earnings Guidance for the Year 2022 May 12
First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.17 profit in 1Q 2021) May 11
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau Apr 01 Evolus, Inc. Reaffirms Revenue Guidance for the Full-Year 2022
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 05
Evolus, Inc. Appoints Christos Monovoukas as Senior Vice President of Corporate Development Mar 03
Evolus, Inc. to Report Q4, 2021 Results on Mar 03, 2022 Feb 18
Evolus, Inc. Receives Acceptance of Submission in Australia, A Pivotal Step in Approval Process for Nuceiva Feb 09
Evolus, Inc. Provides Earnings Guidance for the Year 2022 Jan 27
Forecast to breakeven in 2024 Jan 01
Evolus, Inc. announced that it expects to receive $125 million in funding from Pharmakon Advisors, LP, BPCR Limited Partnership Dec 15
Third quarter 2021 earnings released: US$0.35 loss per share (vs US$0.34 loss in 3Q 2020) Nov 03
Forecast to breakeven in 2023 Sep 23
President recently sold US$784k worth of stock Aug 20
Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.63 loss in 2Q 2020) Aug 06 Evolus, Inc.(NasdaqGM:EOLS) dropped from Russell Microcap Value Index
First quarter 2021 earnings released: EPS US$0.17 (vs US$0.58 loss in 1Q 2020) May 14
Full year 2020 earnings released: US$4.83 loss per share (vs US$3.19 loss in FY 2019) Mar 26
Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement Mar 25
Evolus, Inc. Announces Executive Changes Feb 27 Shareholder Returns 0K16 GB Pharmaceuticals GB Market 7D -1.0% 0.3% 0.4% 1Y 6.2% -4.7% 3.9%
See full shareholder returns
Return vs Market: 0K16 exceeded the UK Market which returned 3.3% over the past year.
Price Volatility Is 0K16's price volatile compared to industry and market? 0K16 volatility 0K16 Average Weekly Movement 8.3% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.3% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0K16's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0K16's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names.
Show more Evolus, Inc. Fundamentals Summary How do Evolus's earnings and revenue compare to its market cap? 0K16 fundamental statistics Market cap US$699.07m Earnings (TTM ) -US$55.46m Revenue (TTM ) US$248.33m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0K16 income statement (TTM ) Revenue US$248.33m Cost of Revenue US$74.64m Gross Profit US$173.69m Other Expenses US$229.15m Earnings -US$55.46m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.88 Gross Margin 69.94% Net Profit Margin -22.33% Debt/Equity Ratio 2,057.9%
How did 0K16 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 01:47 End of Day Share Price 2024/12/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Evolus, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Balaji Prasad Barclays Balaji Prasad Barclays Navann Ty Dietschi BNP Paribas Exane
Show 10 more analysts 